Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: 'Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?' by Xie <i>et al</i>.

Gamboa-Alonso, Carmen Magdalena; Figueroa-Parra, Gabriel; Galarza-Delgado, Dionicio Angel

Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: 'Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?' by Xie et al.

Gamboa-Alonso, Carmen Magdalena; Figueroa-Parra, Gabriel; Galarza-Delgado, Dionicio Angel.

Gamboa-Alonso CM; Servicio de Reumatología, Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico.
Figueroa-Parra G; Servicio de Reumatología, Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico.
Galarza-Delgado DA; Servicio de Reumatología, Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico dgalarza@medicinauanl.mx.

Ann Rheum Dis ; 80(1): e7, 2021 01.

Article in English | MEDLINE | ID: covidwho-612196

Subject(s)

Antimalarials; COVID-19; Rheumatic Diseases; Antimalarials/therapeutic use; Humans; Hydroxychloroquine/therapeutic use; Rheumatic Diseases/drug therapy; SARS-CoV-2

Keywords

antirheumatic agents; arthritis, rheumatoid; autoimmune diseases; hydroxychloroquine; lupus erythematosus, systemic

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Rheumatic Diseases / COVID-19 / Antimalarials Type of study: Prognostic study Limits: Humans Language: English Journal: Ann Rheum Dis Year: 2021 Document Type: Article Affiliation country: Annrheumdis-2020-217633

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google